Status:

COMPLETED

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Johns Hopkins University

Conditions:

Cutaneous Neurofibroma

Eligibility:

All Genders

18-85 years

Phase:

PHASE1

Brief Summary

This study will evaluate the tolerability and effectiveness of three FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 1064nm laser, a 755nm laser, a...

Eligibility Criteria

Inclusion

  • Adult males and females ≥18 years of age
  • Have a diagnosis of Neurofibromatosis Type 1
  • Patients must be seeking treatment for cutaneous Neurofibromas
  • Patients must have ≥ 6 paired cutaneous Neurofibromas (3 to be treated and 3 untreated) that are visible and measure between 2-4mm in size.
  • Able and willing to comply with all visit, treatment and evaluation schedules and requirements
  • Able to understand and provide written informed consent
  • Access to a Smart Phone to be able to take and upload photographs to an application

Exclusion

  • Patients who are undergoing other treatment modalities or investigational agents for their cNF lesions
  • Individuals who cannot give informed consent or adhere to study schedule
  • Actively tanning during the course of the study
  • Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;
  • Known allergy to injectable anesthetics or deoxycholic acid
  • Any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study;
  • Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.

Key Trial Info

Start Date :

June 2 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 19 2024

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT04730583

Start Date

June 2 2021

End Date

April 19 2024

Last Update

February 21 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wellman Center for Photomedicine, Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | DecenTrialz